ClinicalTrials.gg
RecruitingNCT03612726Updated Mar 24, 2025

The Overall Survival of Patients With Unresectable HCC in Real-life

An observational study in Hepatocellular Carcinoma, sponsored by Humanity & Health Medical Group Limited. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Humanity & Health Medical Group Limited · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2018; still recruiting 8 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
10th of 275
5,000 · median 300
Started
2018
with 66 others
Observational
275 of 1,314
120 open now
Primary completion
2025-12
later than 161 of 560 live
Registered
343rd of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 10th largest by planned enrollment of the 275 observational ones that give a count, is one of 67 that started in 2018, is one of 275 observational ones, reaches primary completion later than 161 of the 560 other live ones, and was the 343rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

484 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China).

The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with Unresectable HCC who are treated under real-life clinical practice conditions in Asian Pacific Region

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of unresectable hepatocellular carcinoma
  • Able to comprehend and provide written in accordance with institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • Patients not willing to participate and/or give their written .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
5,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Overall survival

    Overall survival (OS) is defined as the time (days) from the date of unresectable HCC diagnosis to the date of death, due to any reason. Patients alive or lost to follow-up at the time of analysis will be censored at their last date of follow-up

    Time frame: Up to 5 years

Secondary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) is defined as the time (days) from the start of treatment to the date of first observed disease progression (radiological or clinical, whichever is earlier) or death due to any cause, if death occurs before progression is documented

    Time frame: Up to 5 years

  2. Time to progression (TTP)

    Time to progression (TTP) is defined as the time (days) from the start of treatment to the first documented disease progression

    Time frame: Up to 5 years

  3. Duration of treatment

    Duration of treatment, defined by the time interval from the start of treatment to the day of permanent discontinuation of treatment (including death)

    Time frame: Up to 5 years

  4. Frequency and Severity of Adverse Events

    Safety will be evaluated by monitoring and recording the grade 3, 4 and 5 adverse events (AE) occurring during and after treatment throughout follow up of patients.

    Time frame: Up to 5 years

07

Study locations

3 of 3 sites recruiting
  • Beijing 302 Hospital
    Beijing, China
    Recruiting
    • Guofeng Chen, MD · Contact
  • Humanity & Health Medical Group Limited
    Hong Kong, Hong Kong
    Recruiting
    • George Lau, MD · Contact
  • Tokyo University
    Tokyo, Japan
    Recruiting
    • Masao Omata, PhD, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2018 (actual). Primary completion is estimated for Dec 2025, 89 months after the start.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 89 months is above that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2018
First posted
Aug 2, 2018
StartActual
Jul 16, 2018
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03612726
Lead sponsor
Humanity & Health Medical Group Limited
Collaborators
Tokyo University
Responsible party
Sponsor
First posted
Aug 2, 2018
Start date
Jul 16, 2018
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Mar 24, 2025

Study contacts

Danny Wang, PhD
Contact
danny.wang@hnhmgl.com
+852-21160598
Masao Omata, PhD, MD
study chair · Tokyo University
George Lau, MD
study chair · Humanity & Health Medical Group Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion